110
Participants
Start Date
February 2, 2022
Primary Completion Date
September 22, 2023
Study Completion Date
May 28, 2024
Nivolumab
Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
Ipilimumab
Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
RO7247669 2100 mg
RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
Tiragolumab
Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
RO7247669 600 mg
RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Melanoma Institute Australia, North Sydney
Hopital de la Timone, Marseille
Istituto Europeo Di Oncologia, Milan
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
Moffitt Cancer Center, Tampa
Azienda Ospedaliera Universitaria Senese, Siena
APHP - Hospital Saint Louis, Paris
MD Anderson Cancer Center, Houston
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
The Angeles Clinic and Research Institute - W LA Office, Los Angeles
City of Hope, Duarte
Institut Gustave Roussy, Villejuif
Ospedale S.Maria della Misericordia, Perugia
Hospital Universitario Vall d Hebron, Barcelona
Hoffmann-La Roche
INDUSTRY